ERBB2 and breast carcinoma: Similarly, BR105 augmented macrophage phagocytosis of SK-BR-3 breast cancer cells in the presence of anti-HER2 antibody (figure 3B, online supplemental figure S4B), which was developed by BioRay pharmaceutical as a biosimilar to trastuzumab.